TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10093795

Group type: EXPERIMENTAL
Intervention: Policosanol (10 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8113509

Group type: EXPERIMENTAL
Intervention: 5% lidocaine/prilocaine cream (EMLA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3291087

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29441471

Group type: EXPERIMENTAL
Intervention: Bipolar anodal tDCS
Number of subjects: 14

Group type: COMPARATOR
Intervention: Bipolar cathodal tDCS
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 14
Study: 28626983

Group type: EXPERIMENTAL
Intervention: Test product (SM/FP) with 25/125 mcg per inhalation, 2, 6, and 12 inhalations
Number of subjects: 43

Group type: COMPARATOR
Intervention: Reference product (SM/FP) with 25/125 mcg per inhalation, 2, 6, and 12 inhalations
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Test product (12 inhalations)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Reference product (12 inhalations)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Test product (2 and 6 inhalations)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Reference product (2 and 6 inhalations)
Number of subjects: 43
Study: 26496366

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg) with 0.75% ropivacaine and 2% lidocaine with adrenaline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (0.75% ropivacaine and 2% lidocaine with adrenaline)
Number of subjects: 60
Study: 23276413

Group type: EXPERIMENTAL
Intervention: Arthroscopic labral repair
Number of subjects: 36

Group type: COMPARATOR
Intervention: Selective labral debridement
Number of subjects: 36
Study: 21638157

Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study: 18081733

Group type: EXPERIMENTAL
Intervention: Continuous interferon alpha-2b therapy (1, 2 or 3 MIU TIW depending on response)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Cyclical interferon alpha-2b therapy (3 MIU TIW for 24 weeks per relapse)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Both groups (continuous and cyclical therapy)
Number of subjects: 499
Study: 16781242

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 9014

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9014
Study: 14636196

Group type: EXPERIMENTAL
Intervention: Thiabendazole, 20 mg/kg twice daily for 1 day, with repeat treatment after 10 days
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Thiabendazole
Number of subjects: 23
Study: 12095157

Group type: EXPERIMENTAL
Intervention: Activated Protein C (APC) 12.5 U [2.5 microg]/kg body wt per hour
Number of subjects: 132

Group type: COMPARATOR
Intervention: Unfractionated Heparin (8 U/kg body wt per hour)
Number of subjects: 132
Study: 9687996

Group type: EXPERIMENTAL
Intervention: Surgical treatment (ST)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Endoscopic management (EM)
Number of subjects: 220
Study: 7505809

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 5 micrograms/kg self-administered subcutaneously on days when chemotherapy was not given.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control arm (no G-CSF) receiving weekly chemotherapy with cisplatin and etoposide alternating with ifosfamide and doxorubicin.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) arm receiving weekly chemotherapy with G-CSF.
Number of subjects: 40
Study: 2679494

Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 mg b.i.d. for 8 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 781232

Group type: EXPERIMENTAL
Intervention: Fenoprofen calcium
Number of subjects: 27

Group type: COMPARATOR
Intervention: Acetylsalicylic acid
Number of subjects: 27
Study: 29757013

Group type: EXPERIMENTAL
Intervention: Behavioral sleep intervention (sleep hygiene practices and standardized behavioral strategies delivered by trained school nurses)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Usual community care (Control group)
Number of subjects: 334
Study: 28601084

Group type: EXPERIMENTAL
Intervention: Probiotic oral suspension (POS) for 3 weeks
Number of subjects: 60
Study: 25010250

Group type: EXPERIMENTAL
Intervention: Booklet patient decision aid (intervention group)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard information (control group)
Number of subjects: 122
Study: 22850326

Group type: EXPERIMENTAL
Intervention: 5 g/100 g alginate
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control (no added fibre)
Number of subjects: 121
Study: 22303756

Group type: EXPERIMENTAL
Intervention: Unicompartmental knee arthroplasty
Number of subjects: 34

Group type: COMPARATOR
Intervention: Total knee arthroplasty
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 18330493

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 16820123

Group type: EXPERIMENTAL
Intervention: Mixed frequency (80 Hz and 2 Hz, 3 seconds each)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Fixed frequency (20 Hz)
Number of subjects: 152
Study: 15662744

Group type: EXPERIMENTAL
Intervention: Behavioral graded activity
Number of subjects: 105

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 105
Study: 10674588

Group type: EXPERIMENTAL
Intervention: Low-fat, vegetarian diet
Number of subjects: 33
Study: 9131896

Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: GHB
Number of subjects: 34

Group type: COMPARATOR
Intervention: GHRH
Number of subjects: 34

Group type: COMPARATOR
Intervention: L-arginine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 8442968

Group type: EXPERIMENTAL
Intervention: d‐tubocurarine (priming drug) + pancuronium (intubating dose) - Group C
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: pancuronium (priming drug) + d‐tubocurarine (intubating dose) - Group D
Number of subjects: 90

Group type: COMPARATOR
Intervention: normal saline (control) - Groups A and B
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: d‐tubocurarine (intubating dose) - Groups B, D, and F
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: pancuronium (intubating dose) - Groups A, C, and E
Number of subjects: 90
Study: 30796424

Group type: EXPERIMENTAL
Intervention: Targeted therapy (tyrosine kinase inhibitor for EGFR mutation-positive patients)
Number of subjects: 8947

Group type: EXPERIMENTAL
Intervention: Targeted therapy (tyrosine kinase inhibitor for ALK-positive patients)
Number of subjects: 8947

Group type: EXPERIMENTAL
Intervention: Chemotherapy monotherapy
Number of subjects: 8947

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 8947

Group type: EXPERIMENTAL
Intervention: EGFR-positive and ALK-positive patients
Number of subjects: 8947

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 8947
Study: 29405495

Group type: EXPERIMENTAL
Intervention: Branded alcohol portrayals
Number of subjects: 758

Group type: COMPARATOR
Intervention: Unbranded alcohol portrayals
Number of subjects: 758
Study: 27319096

Group type: EXPERIMENTAL
Intervention: Spinal block (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: US-guided caudal epidural block (n = 30)
Number of subjects: 60
Study: 23770005

Group type: EXPERIMENTAL
Intervention: 50 mg golimumab
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: 100 mg golimumab
Number of subjects: 464

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study: 22076253

Group type: EXPERIMENTAL
Intervention: Letrozole (5-year treatment)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 20608242

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 18600358

Group type: EXPERIMENTAL
Intervention: Perioperative corticosteroids
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Rubber drain
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no drug or drain)
Number of subjects: 22
Study: 15765387

Group type: EXPERIMENTAL
Intervention: Enteryx implantation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 64
Study: 12351470

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (8 mg)
Number of subjects: 3600

Group type: COMPARATOR
Intervention: Glyburide (15 mg)
Number of subjects: 3600

Group type: COMPARATOR
Intervention: Metformin (2 g)
Number of subjects: 3600

Group type: EXPERIMENTAL
Intervention: Rosiglitazone, Glyburide, Metformin
Number of subjects: 3600
Study: 12198782

Group type: EXPERIMENTAL
Intervention: Cued to form an image of a specified object (e.g., tiger)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Instructions encouraged subjects to discard the image and to avoid searching for it
Number of subjects: 0
Study: 7498100

Group type: EXPERIMENTAL
Intervention: 2.5 mg cholecalciferol (vitamin D3)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 1901204

Group type: EXPERIMENTAL
Intervention: Ceftriaxone sodium, 1 g/d intravenously
Number of subjects: 1238

Group type: COMPARATOR
Intervention: Cefamandole naftate and sodium carbonate, 1 g intravenously every 6 hours
Number of subjects: 1238
Study: 7045605

Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lignocaine
Number of subjects: 30
Study: 30406883

Group type: EXPERIMENTAL
Intervention: 18 Hz dTMS (HF, 13 patients)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 1 Hz dTMS (LF, 10 patients)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham treatment (Sham, 10 patients)
Number of subjects: 33
Study: 28720103

Group type: EXPERIMENTAL
Intervention: ICT-based intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional intervention group
Number of subjects: 0
Study: 26331383

Group type: EXPERIMENTAL
Intervention: Vortioxetine (10/20 mg)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Escitalopram (10/20 mg)
Number of subjects: 447
Study: 23847964

Group type: EXPERIMENTAL
Intervention: Combined traditional Chinese medicine and western medicine treatment (antivenom serum 6000 U for 5 days, anti pit viper No. 2 concentrated decoction 300 mL twice to three times daily for 5 days)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Traditional Chinese medicine treatment (anti pit viper No. 2 concentrated decoction 300 mL twice to three times daily for 5 days)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Western medicine treatment (antivenom serum 6000 U for 5 days)
Number of subjects: 98
Study: 20676771

Group type: COMPARATOR
Intervention: Mesalamine 500 mg suppository administered BID
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Mesalamine 1 g suppository administered QHS
Number of subjects: 97
Study: 19643831

Group type: EXPERIMENTAL
Intervention: Patient-held manual intervention
Number of subjects: 249

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 249
Study: 17315307

Group type: EXPERIMENTAL
Intervention: HsHMP (250 mg of total anthocyanins per dose)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Lisinopril (10 mg)
Number of subjects: 193
Study: 15014181

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 4742

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 4742
Study: 11259798

Group type: EXPERIMENTAL
Intervention: Neuroendocrine reactivity measured by urinary adrenaline and cortisol during work and recovery
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Cortisol reactivity during work and recovery
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Adrenaline baseline level and recovery during the day off-work
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Job characteristics
Number of subjects: 59
Study: 9749629

Group type: EXPERIMENTAL
Intervention: Intervention vendors using a simple system for water purification and storage, handwashing, and beverage storage (dilute bleach 4.95% free available chlorine, narrow-mouth plastic vessels, handwashing soap, and education).
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control vendors (no intervention).
Number of subjects: 83
Study: 7835373

Group type: EXPERIMENTAL
Intervention: Celiprolol 400 mg once daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once daily
Number of subjects: 20
Study: 3076609

Group type: EXPERIMENTAL
Intervention: Frone cream 20,000 IU/g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frone eye drops (500,000‐1,000,000 U)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frone cream or drops
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment of interferon in families
Number of subjects: 0
Study: 31418808

Group type: EXPERIMENTAL
Intervention: Sexual health intervention (n = 38)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Alcohol prevention intervention (n = 40)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control (n = 40)
Number of subjects: 118
Study: 28763892

Group type: EXPERIMENTAL
Intervention: Suction drainage
Number of subjects: 1009

Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 1009
Study: 25728724

Group type: EXPERIMENTAL
Intervention: 6-component quality improvement intervention
Number of subjects: 25000

Group type: COMPARATOR
Intervention: Control group (no intervention during baseline period)
Number of subjects: 25000
Study: 24207068

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 24 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 48
Study: 21777267

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich fibrin (PRF)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional open flap debridement
Number of subjects: 32
Study: 19369030

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Number of subjects: 110

Group type: COMPARATOR
Intervention: Negative posttraumatic cognitions
Number of subjects: 110
Study: 16677714

Group type: EXPERIMENTAL
Intervention: 250 mg/day D-cycloserine (DCS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 14984380

Group type: EXPERIMENTAL
Intervention: 3 MU interferon‐alpha2b plus ribavirin (1000‐1200 mg) for 12 months (Group 1)
Number of subjects: 35

Group type: COMPARATOR
Intervention: 3 MU interferon‐alpha2b plus ribavirin (1000‐1200 mg) for 12 months (Group 2)
Number of subjects: 35
Study: 11352963

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine and mitoxantrone (HAM)
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Idarubicin induction
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Study AML-BFM 93
Number of subjects: 471

Group type: COMPARATOR
Intervention: Study AML-BFM 93 vs Study AML-BFM 87 for high-risk patients
Number of subjects: 471

Group type: COMPARATOR
Intervention: Study AML-BFM 93 vs Study AML-BFM 87 for standard-risk patients
Number of subjects: 471
Study: 9393903

Group type: EXPERIMENTAL
Intervention: CPM at 0 to 70 degrees (0 to 70 CPM)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: CPM at 0 to 40 degrees (0 to 40 CPM)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No CPM
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: CPM (both 0 to 40 and 0 to 70 degrees)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 0 to 70 CPM
Number of subjects: 53
Study: 7957657

Group type: EXPERIMENTAL
Intervention: 0.016 x 0.022‐inch sectional arches including a reverse closing loop for maxillary canines retraction (mean period 7.75 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.016 x 0.022‐inch Gjessing retraction arches for maxillary canines retraction (mean period 6.25 months)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.016 x 0.022‐inch sectional arches with reverse closing loop for mandibular canines retraction (mean period 7.75 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.016 x 0.022‐inch Gjessing arches for mandibular canines retraction (mean period 6 months)
Number of subjects: 20
Study: 3270085

Group type: EXPERIMENTAL
Intervention: cyclosporin
Number of subjects: 64

Group type: COMPARATOR
Intervention: cyclophosphamide
Number of subjects: 64
Study: 31787053

Group type: EXPERIMENTAL
Intervention: Usual care plus a group‐based behavioral intervention focused on patient activation and engagement (n=332)
Number of subjects: 647

Group type: COMPARATOR
Intervention: Usual care (n=315)
Number of subjects: 647
Study: 28396565

Group type: EXPERIMENTAL
Intervention: Topical borneol
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 26809257

Group type: EXPERIMENTAL
Intervention: Learn to be safe with Emmy and friends™ (5 sessions of 1 hour each)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Parent discussion monitor
Number of subjects: 72
Study: 24356256

Group type: EXPERIMENTAL
Intervention: Motavizumab 30 mg/kg
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Motavizumab 100 mg/kg
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 22572834

Group type: EXPERIMENTAL
Intervention: Gut Balance™ (synbiotic supplement)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Acacia gum (control)
Number of subjects: 22
Study: 19284123

Group type: EXPERIMENTAL
Intervention: Femoral-sciatic nerve block
Number of subjects: 1550

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 1550

Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Number of subjects: 1550
Study: 17245135

Group type: EXPERIMENTAL
Intervention: Dermabond (octyl‐2‐cyanoacrylate)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Traditional sutures
Number of subjects: 22
Study: 15038640

Group type: EXPERIMENTAL
Intervention: Magnification lenses
Number of subjects: 19

Group type: COMPARATOR
Intervention: Traditional safety glasses
Number of subjects: 19
Study: 12581548

Group type: EXPERIMENTAL
Intervention: Clarithromycin ER 500-mg tablet QD for 7 days
Number of subjects: 233

Group type: COMPARATOR
Intervention: Clarithromycin IR 250-mg tablet BID for 7 days
Number of subjects: 233
Study: 9921849

Group type: EXPERIMENTAL
Intervention: Inpatient physical rehabilitation for 3 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Exercises performed at home (control treatment)
Number of subjects: 50
Study: 7478086

Group type: EXPERIMENTAL
Intervention: Pancuronium, Vecuronium, Atracurium (administered via intramuscular and intravascular routes)
Number of subjects: 0
Study: 2403747

Group type: EXPERIMENTAL
Intervention: APDT vaccine
Number of subjects: 82

Group type: COMPARATOR
Intervention: DTP vaccine
Number of subjects: 82
Study: 377819

Group type: EXPERIMENTAL
Intervention: Fumaria-preparation Oddibil
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 30895429

Group type: EXPERIMENTAL
Intervention: Extended gastrectomy
Number of subjects: 587

Group type: COMPARATOR
Intervention: Standard gastrectomy
Number of subjects: 587
Study: 30685166

Group type: EXPERIMENTAL
Intervention: Amino acid infusion initiated immediately after induction of anesthesia (n=33)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard care (n=36)
Number of subjects: 69
Study: 28104293

Group type: EXPERIMENTAL
Intervention: Instructor-led debriefing including performance feedback (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No debriefing (control; n = 10)
Number of subjects: 20
Study: 25592987

Group type: EXPERIMENTAL
Intervention: Probiotic and peanut oral immunotherapy (PPOIT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 24119239

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both active and sham rTMS
Number of subjects: 21
Study: 21734254

Group type: EXPERIMENTAL
Intervention: Hierarchical sequencing (HS) model
Number of subjects: 48

Group type: COMPARATOR
Intervention: Logically sequenced (LS) module
Number of subjects: 48
Study: 19332525

Group type: EXPERIMENTAL
Intervention: Deductive treatment (N = 16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Inductive treatment (N = 16)
Number of subjects: 32
Study: 17879411

Group type: EXPERIMENTAL
Intervention: Ferrous succinate combined with triple therapy for H pylori eradication
Number of subjects: 86

Group type: COMPARATOR
Intervention: Ferrous succinate only (Control)
Number of subjects: 86
Study: 15346355

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (ISMO) at a dose of 20 mg twice a day for 2 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo tablets for 2 weeks
Number of subjects: 31
Study: 11249221

Group type: EXPERIMENTAL
Intervention: Plate fixation plus operative arthroscopy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Plate fixation only (Control)
Number of subjects: 19
Study: 9544901

Group type: EXPERIMENTAL
Intervention: rhGH 4.5 IU/m2/day
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: rhGH 3 IU/m2/day
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: rhGH 3 IU/m2/day for the first year and 4.5 IU/m2/day thereafter
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: rhGH therapy (all groups)
Number of subjects: 223
Study: 7987887

Group type: EXPERIMENTAL
Intervention: Metronidazole plus scaling and root planing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Positive-control (placebo) plus scaling and root planing
Number of subjects: 0
Study: 1968784

Group type: EXPERIMENTAL
Intervention: esmolol 200 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: esmolol 100 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study: 343991

Group type: EXPERIMENTAL
Intervention: 2% sodium fusidate ointment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral antibiotic therapy (clindamycin, erythromycin, or flucloxacillin) plus placebo ointment
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bacteriological investigations
Number of subjects: 90
Study: 31503789

Group type: EXPERIMENTAL
Intervention: Flexible light field reconstruction method using a conventional camera from random 3D positions and angles.
Number of subjects: 0
Study: 27910711

Group type: EXPERIMENTAL
Intervention: Endometrial injury through hysteroscopy
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard protocol without any intervention (Control)
Number of subjects: 103